Daewoong Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Daewoong Pharmaceutical has a total shareholder equity of ₩934.8B and total debt of ₩548.8B, which brings its debt-to-equity ratio to 58.7%. Its total assets and total liabilities are ₩1,877.4B and ₩942.5B respectively. Daewoong Pharmaceutical's EBIT is ₩128.6B making its interest coverage ratio 32.1. It has cash and short-term investments of ₩110.3B.
Key information
58.7%
Debt to equity ratio
₩548.75b
Debt
| Interest coverage ratio | 32.1x |
| Cash | ₩110.31b |
| Equity | ₩934.81b |
| Total liabilities | ₩942.54b |
| Total assets | ₩1.88t |
Recent financial health updates
Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly
Oct 15
We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt
Jul 04Recent updates
There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price
Nov 06Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly
Oct 15Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate
Aug 13Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings
Jul 24We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt
Jul 04Financial Position Analysis
Short Term Liabilities: A069620's short term assets (₩589.6B) exceed its short term liabilities (₩588.5B).
Long Term Liabilities: A069620's short term assets (₩589.6B) exceed its long term liabilities (₩354.1B).
Debt to Equity History and Analysis
Debt Level: A069620's net debt to equity ratio (46.9%) is considered high.
Reducing Debt: A069620's debt to equity ratio has reduced from 62.4% to 58.7% over the past 5 years.
Debt Coverage: A069620's debt is not well covered by operating cash flow (15.4%).
Interest Coverage: A069620's interest payments on its debt are well covered by EBIT (32.1x coverage).